pembrolizumab,lenvatinib
merck,eisai
['lenva', 'leap-002', 'hcc', 'pembro']
although the combination use of lenvatinib+pembrolizumab did not induce statistically significant differences in the end points, the leap-002 trial induced the longest seen median os with lenvatinib alone in patients with unresectable #hcc #esmo2022. 
Oncology news and insights from leading researchers and cancer centers.